The dual targeting of CD137 and HER is attractive because it makes it possible to link CD137 and T-cells in close proximity to HER2-positive tumor cells and to generate a strong signal to tumor antigen-specific T-cells eliciting anti-tumor activity. Here, TNFRSF9 is linked to neoplasm.